2016 IPO

OncoCyte Stock

Focused on cancers with large patient populations and significant unmet need.

Sign up today and learn more about OncoCyte Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About OncoCyte Stock

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care costs Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.


President & CEO

William Annett




marketwatch - Dec, 16 2022

Oncocyte cuts 40% of staff

benzinga - Dec, 2 2022

Expert Ratings for OncoCyte

massdevice - Apr, 20 2021

Oncocyte acquires Chronix Biomedical

Yankee Analysts - Jun, 27 2018

Oncocyte Corp (OCX) Placed Under the Lens

The Ledger Gazette - Jun, 24 2018

OncoCyte (OCX) Stock Price Up 37%

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: